Targeting liver myofibroblasts

a novel approach in anti-fibrogenic therapy

Angela Douglass, Karen Wallace, Matthew Koruth, Caroline Barelle, Andrew J Porter, Matthew C Wright

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Chronic liver disease results in a liver-scarring response termed fibrosis. Excessive scarring leads to cirrhosis, which is associated with high morbidity and mortality. The only treatment for liver cirrhosis is liver transplantation; therefore, much attention has been directed toward therapies that will slow or reverse fibrosis. Although anti-fibrogenic therapies have been shown to be effective in experimental animal models, licensed therapies have yet to emerge. A potential problem for any anti-fibrogenic therapy in the liver is the existence of the body's major drug metabolising cell (the hepatocyte) adjacent to the primary fibrosis-causing cell, the myofibroblast. This article reviews the development of a human recombinant single-chain antibody (scAb) that binds to the surface of myofibroblasts. This antibody binds specifically to myofibroblasts in fibrotic mouse livers. When conjugated with a compound that stimulates myofibroblast apoptosis, the antibody directs the specific apoptosis of myofibroblasts with greater specificity and efficacy than the free compound. The antibody also reduces the adverse effect of liver macrophage apoptosis and-in contrast to the free compound-reversed fibrosis in the sustained injury model used. These data suggest that specifically stimulating the apoptosis of liver myofibroblasts using a targeting antibody has potential in the treatment of liver fibrosis.
Original languageEnglish
Pages (from-to)405-15
Number of pages11
JournalHepatology International
Volume2
Issue number4
Early online date3 Sep 2008
DOIs
Publication statusPublished - Dec 2008

Keywords

  • C1-3
  • gliotoxin
  • hepatic stellate cell
  • fibrosis
  • Kupffer cell
  • matrix metalloproteinase 13
  • hepatic stellate cells
  • activated receptor-gamma
  • primary biliary-cirrhosis
  • pregane-X-receptor
  • salvianolic acid-B
  • NF-Kappa-B
  • rat-liver
  • TGF-beta
  • Kuppfer cells
  • in-vitro

Cite this

Targeting liver myofibroblasts : a novel approach in anti-fibrogenic therapy. / Douglass, Angela; Wallace, Karen; Koruth, Matthew; Barelle, Caroline; Porter, Andrew J; Wright, Matthew C.

In: Hepatology International, Vol. 2, No. 4, 12.2008, p. 405-15.

Research output: Contribution to journalArticle

Douglass, Angela ; Wallace, Karen ; Koruth, Matthew ; Barelle, Caroline ; Porter, Andrew J ; Wright, Matthew C. / Targeting liver myofibroblasts : a novel approach in anti-fibrogenic therapy. In: Hepatology International. 2008 ; Vol. 2, No. 4. pp. 405-15.
@article{7657419bf3884eb698122eaaebc6a54f,
title = "Targeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy",
abstract = "Chronic liver disease results in a liver-scarring response termed fibrosis. Excessive scarring leads to cirrhosis, which is associated with high morbidity and mortality. The only treatment for liver cirrhosis is liver transplantation; therefore, much attention has been directed toward therapies that will slow or reverse fibrosis. Although anti-fibrogenic therapies have been shown to be effective in experimental animal models, licensed therapies have yet to emerge. A potential problem for any anti-fibrogenic therapy in the liver is the existence of the body's major drug metabolising cell (the hepatocyte) adjacent to the primary fibrosis-causing cell, the myofibroblast. This article reviews the development of a human recombinant single-chain antibody (scAb) that binds to the surface of myofibroblasts. This antibody binds specifically to myofibroblasts in fibrotic mouse livers. When conjugated with a compound that stimulates myofibroblast apoptosis, the antibody directs the specific apoptosis of myofibroblasts with greater specificity and efficacy than the free compound. The antibody also reduces the adverse effect of liver macrophage apoptosis and-in contrast to the free compound-reversed fibrosis in the sustained injury model used. These data suggest that specifically stimulating the apoptosis of liver myofibroblasts using a targeting antibody has potential in the treatment of liver fibrosis.",
keywords = "C1-3, gliotoxin, hepatic stellate cell, fibrosis, Kupffer cell, matrix metalloproteinase 13, hepatic stellate cells, activated receptor-gamma, primary biliary-cirrhosis, pregane-X-receptor, salvianolic acid-B, NF-Kappa-B, rat-liver, TGF-beta, Kuppfer cells, in-vitro",
author = "Angela Douglass and Karen Wallace and Matthew Koruth and Caroline Barelle and Porter, {Andrew J} and Wright, {Matthew C}",
year = "2008",
month = "12",
doi = "10.1007/s12072-008-9093-y",
language = "English",
volume = "2",
pages = "405--15",
journal = "Hepatology International",
issn = "1936-0541",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Targeting liver myofibroblasts

T2 - a novel approach in anti-fibrogenic therapy

AU - Douglass, Angela

AU - Wallace, Karen

AU - Koruth, Matthew

AU - Barelle, Caroline

AU - Porter, Andrew J

AU - Wright, Matthew C

PY - 2008/12

Y1 - 2008/12

N2 - Chronic liver disease results in a liver-scarring response termed fibrosis. Excessive scarring leads to cirrhosis, which is associated with high morbidity and mortality. The only treatment for liver cirrhosis is liver transplantation; therefore, much attention has been directed toward therapies that will slow or reverse fibrosis. Although anti-fibrogenic therapies have been shown to be effective in experimental animal models, licensed therapies have yet to emerge. A potential problem for any anti-fibrogenic therapy in the liver is the existence of the body's major drug metabolising cell (the hepatocyte) adjacent to the primary fibrosis-causing cell, the myofibroblast. This article reviews the development of a human recombinant single-chain antibody (scAb) that binds to the surface of myofibroblasts. This antibody binds specifically to myofibroblasts in fibrotic mouse livers. When conjugated with a compound that stimulates myofibroblast apoptosis, the antibody directs the specific apoptosis of myofibroblasts with greater specificity and efficacy than the free compound. The antibody also reduces the adverse effect of liver macrophage apoptosis and-in contrast to the free compound-reversed fibrosis in the sustained injury model used. These data suggest that specifically stimulating the apoptosis of liver myofibroblasts using a targeting antibody has potential in the treatment of liver fibrosis.

AB - Chronic liver disease results in a liver-scarring response termed fibrosis. Excessive scarring leads to cirrhosis, which is associated with high morbidity and mortality. The only treatment for liver cirrhosis is liver transplantation; therefore, much attention has been directed toward therapies that will slow or reverse fibrosis. Although anti-fibrogenic therapies have been shown to be effective in experimental animal models, licensed therapies have yet to emerge. A potential problem for any anti-fibrogenic therapy in the liver is the existence of the body's major drug metabolising cell (the hepatocyte) adjacent to the primary fibrosis-causing cell, the myofibroblast. This article reviews the development of a human recombinant single-chain antibody (scAb) that binds to the surface of myofibroblasts. This antibody binds specifically to myofibroblasts in fibrotic mouse livers. When conjugated with a compound that stimulates myofibroblast apoptosis, the antibody directs the specific apoptosis of myofibroblasts with greater specificity and efficacy than the free compound. The antibody also reduces the adverse effect of liver macrophage apoptosis and-in contrast to the free compound-reversed fibrosis in the sustained injury model used. These data suggest that specifically stimulating the apoptosis of liver myofibroblasts using a targeting antibody has potential in the treatment of liver fibrosis.

KW - C1-3

KW - gliotoxin

KW - hepatic stellate cell

KW - fibrosis

KW - Kupffer cell

KW - matrix metalloproteinase 13

KW - hepatic stellate cells

KW - activated receptor-gamma

KW - primary biliary-cirrhosis

KW - pregane-X-receptor

KW - salvianolic acid-B

KW - NF-Kappa-B

KW - rat-liver

KW - TGF-beta

KW - Kuppfer cells

KW - in-vitro

U2 - 10.1007/s12072-008-9093-y

DO - 10.1007/s12072-008-9093-y

M3 - Article

VL - 2

SP - 405

EP - 415

JO - Hepatology International

JF - Hepatology International

SN - 1936-0541

IS - 4

ER -